Hanmei Lou

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial

Xiangyu Gao, Nong Xu, Ziyu Li et al. · The Lancet Oncology · 2023 · 197 citations

Pharmacy, Oncology, Pharmacology +16

Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China

Xiaohua Wu, Yang Sun, Hongying Yang et al. · The Lancet · 2024 · 102 citations

Medicine, Oncology, Pharmacology +13

Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)

Xiaohua Wu, Jiafu Ji, Hanmei Lou et al. · Gynecologic Oncology · 2022 · 62 citations

Medicine, Oncology, Pharmacology +16

Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study

Hanmei Lou, Hongbing Cai, Xin Huang et al. · Clinical Cancer Research · 2024 · 57 citations · Full text

Medicine, Oncology, Pharmacology +17

SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study

Jifeng Feng, Dihong Tang, Jing Wang et al. · Clinical Cancer Research · 2022 · 56 citations

Medicine, Oncology, Pharmacology +15